{"id":8,"date":"2018-05-09T16:22:54","date_gmt":"2018-05-09T07:22:54","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/?page_id=8"},"modified":"2026-02-13T16:29:07","modified_gmt":"2026-02-13T07:29:07","slug":"research","status":"publish","type":"page","link":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/research","title":{"rendered":"\u7814\u7a76"},"content":{"rendered":"<div>\n<style type=\"text\/css\">\ndiv.contents.matchHeight {\n\theight: auto !important;\n}\n<span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">\ufeff<\/span>\n<\/style>\n<\/div>\n<div class=\"trigger\" id=\"tab01\"><\/div>\n<div class=\"trigger\" id=\"tab02\"><\/div>\n<div class=\"trigger\" id=\"tab03\"><\/div>\n<div class=\"trigger\" id=\"tab04\"><\/div>\n<div class=\"trigger\" id=\"tab05\"><\/div>\n<div class=\"trigger\" id=\"tab06\"><\/div>\n<div class=\"trigger\" id=\"tab07\"><\/div>\n<div class=\"trigger\" id=\"tab08\"><\/div>\n<div class=\"trigger\" id=\"tab09\"><\/div>\n<div class=\"trigger\" id=\"tab10\"><\/div>\n<ul class=\"tabBtn clearfix\">\n<li><a href=\"#tab01\">2026\u5e74<\/a><\/li>\n<li><a href=\"#tab02\">2025\u5e74<\/a><\/li>\n<li><a href=\"#tab03\">2024\u5e74<\/a><\/li>\n<li><a href=\"#tab04\">2023\u5e74<\/a><\/li>\n<li><a href=\"#tab05\">2022\u5e74<\/a><\/li>\n<li><a href=\"#tab06\">2021\u5e74<\/a><\/li>\n<li><a href=\"#tab07\">2020\u5e74<\/a><\/li>\n<li><a href=\"#tab08\">2019\u5e74<\/a><\/li>\n<li><a href=\"#tab09\">2018\u5e74<\/a><\/li>\n<li><a href=\"#tab10\">2017\u5e74<\/a><\/li>\n<\/ul>\n<div class=\"tabContents\">\n<div class=\"content\">\n<h3 class=\"m_o0\">2026\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Yamashita K, Nishio K, Mizutani S, Nishimura Y, Tarui M, Sakamoto S, Iwasaki K, Hida E, Nakai S, Hagi T, Momose K, Saito T, Tanaka K, Makino T, Takahashi T, Kurokawa Y, Nakajima K, Eguchi H, Doki Y. A randomized controlled trial evaluating the effects of anamorelin in postoperative patients with upper gastrointestinal cancer: protocol for the CLEAR-UP study. Jpn. J. Clin. Oncol. 2026 Jan 16:hyaf223.<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>\u7b39\u539f\u7950\u4ecb, \u68ee\u5185\u5bdb\u660e, \u5c0f\u5742\u660e\u5b50, \u6709\u5b89\u5eb7\u884c, \u9577\u8c37\u5ddd\u8cb4\u5927, \u98db\u7530\u82f1\u7950. FDA\u30ac\u30a4\u30c0\u30f3\u30b9\u306b\u5b66\u3076 : \u85ac\u4e8b\u76ee\u7684\u306e\u5229\u7528\u3092\u898b\u636e\u3048\u305fRWD\u306e\u54c1\u8cea\u7ba1\u7406 &#8211; \u81e8\u5e8a\u30c7\u30fc\u30bf\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u306e\u8996\u70b9\u304b\u3089EHR\/\u533b\u7642\u8acb\u6c42\u30c7\u30fc\u30bf\u3092\u8003\u5bdf\u3059\u308b -. \u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a\u7b2c17\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a. 2026\u5e742\u670819\u65e5 &#8211; 21\u65e5. \u795e\u6238\u56fd\u969b\u4f1a\u8b70\u5834.<\/li>\n<li>\u7b39\u539f\u7950\u4ecb, \u6751\u7530\u6cf0\u4e09, \u6a29\u6cf0\u53f2, \u6b66\u7530\u7406\u5b8f, \u98db\u7530\u82f1\u7950. \u75c5\u9662\u30c7\u30fc\u30bf\u30a6\u30a7\u30a2\u30cf\u30a6\u30b9\u304a\u3088\u3073\u75be\u60a3\u30ec\u30b8\u30b9\u30c8\u30ea\u3092\u7528\u3044\u305f\u81e8\u5e8a\u8a66\u9a13\u306e\u9069\u683c\u57fa\u6e96\u304a\u3088\u3073\u30a2\u30a6\u30c8\u30ab\u30e0\u9805\u76ee\u306e\u62bd\u51fa\u53ef\u80fd\u6027 &#8211; \u6025\u6027\u865a\u8840\u6027\u8133\u5352\u4e2d\u306e\u81e8\u5e8a\u8a66\u9a13\u3092\u5bfe\u8c61\u3068\u3057\u3066 -. \u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a\u7b2c17\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a. 2026\u5e742\u670819\u65e5 &#8211; 21\u65e5. \u795e\u6238\u56fd\u969b\u4f1a\u8b70\u5834.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2025\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Watabe T, Mukai K, Naka S, Sasaki H, Kamiya T, Hayakawa T, Fukuhara A, Takano T, Shirakami Y, Ooe K, Shigeno S, Okamura S, Masumura K, Hida E, Haba H, Toyoshima A, Isohashi K, Shimomura I, Tomiyama N. First-in-Human Study of [<sup>211<\/sup>At]NaAt as Targeted \u03b1-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). Journal of Nuclear Medicine December 2025, 66 (12) 1941-1947.<\/li>\n<li>So R, Nouso K, Matsushita S, Yoshiji H, Yuzuriha T, Hida E, Nishimura H, Takagi Y, Horie Y. Efficacy and safety of a digital therapeutic for alcohol dependence: A multicenter, open-label, randomized controlled trial. Psychiatry Clin Neurosci. 2025 Jul 28.<\/li>\n<li>Sasahara Y, Gon Y, Hida E. Association between Acute Care Accessibility and in-Hospital Mortality among Patients with Acute Ischemic Stroke. JMA Journal. Apr 2025.\u00a0 <span>8(2):417-429.<\/span><\/li>\n<li>Dohi T, Ishihara T, Kida H, Nakamura D, Kikuchi A, Kawai T, Mori N, Okamoto N, Ueda Y, Shutta R, Ichikawa M, Mano T, Watanabe T, Higuchi Y, Nishino M, Hida E, Sato T, Hikoso S, Nakatani D, Sotomi Y, Sakata Y. Comparison of drug-coated versus conventional balloons for the side branch of the bifurcation lesion &#8211; multicenter randomized controlled study &#8211; (OCVC-BIF): Design and rationale. Cardiovascular revascularization medicine : including molecular interventions. Mar 2025.<\/li>\n<li>Toyoda K, Yoshimura S, Nakai M, Wada S, Miwa K, Koge J, Yoshida T, Kamiyama K, Mizoue T, Hatano T, Yoshida Y, Sasahara Y, Ishigami A, Iwanaga Y, Miyamoto Y, Minematsu K, Kobayashi S, Koga M, Japan Stroke Data Bank Investigators. Severity, Outcomes, and their Secular Changes in 33,870 Ischemic Stroke Patients with Atrial Fibrillation in a Hospital-Based Registry: Japan Stroke Data Bank. Journal of Atherosclerosis and Thrombosis. Mar 2025. 32(3):308-320.<\/li>\n<li>Kaji H, Yokooji T, Taogoshi T, Izumitani S, Hida E, Matsuo H. Assessment of Risk of Acidosis in Patients with Mild-to-Moderate Chronic Kidney Disease Treated with Intravenous Branched-Chain Amino Acid-Enriched Solution: A Propensity Score Matching Analysis. Biological &amp; pharmaceutical bulletin. Jan 2025.\u00a048(1):46-50.<\/li>\n<li>Komaki H, Takeshita E, Kunitake K, Ishizuka T, Shimizu-Motohashi Y, Ishiyama A, Sasaki M, Yonee C, Maruyama S, Hida E, Aoki Y. Phase 1\/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy. Cell Reports Medicine. Jan 2025. 6(1):101901-101901.<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>Sato T, Hida E. Estimation and testing methods for delayed-start design as an alternative to single-arm trials in small clinical trials. 46th Annual Conference of the ISCB. 24-28 August, 2025. Basel, Switzerland.<\/li>\n<li>Okamura S, Hida E. Confirming assay sensitivity in 2-arm non-inferiority trial using meta-analytic-predictive approach. 46th Annual Conference of the ISCB. 24-28 August, 2025. Basel, Switzerland.<\/li>\n<li>Sasahara Y, Murata T, Gon Y, Takeda T, Hida E. Relevance of electronic medical records for clinical trial eligibilities and outcomes: A feasibility assessment in acute stroke studies. 46th Annual Conference of the ISCB. 24-28 August, 2025. Basel, Switzerland.<\/li>\n<li>Hida E, Okamura S, Sato T, Imamura T, Baba T, Hasegawa T. Assessment of assay sensitivity in non-inferiority trials using aggregate data from a historical trial: A population adjustment approach. 46th Annual Conference of the ISCB. 24-28 August, 2025. Basel, Switzerland.<\/li>\n<li>\u7b39\u539f\u7950\u4ecb, \u6751\u7530\u6cf0\u4e09, \u6a29\u6cf0\u53f2, \u6b66\u7530\u7406\u5b8f, \u98db\u7530\u82f1\u7950. \u65e5\u5e38\u8a3a\u7642\u8a18\u9332\u3092\u7528\u3044\u305f\u81e8\u5e8a\u8a66\u9a13\u306e\u767b\u9332\u7968\u30c7\u30fc\u30bf\u69cb\u7bc9\u306e\u691c\u8a0e.\u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a\u7b2c16\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a. 2025\u5e742\u670828\u65e5-3\u67081\u65e5. \u30d1\u30b7\u30d5\u30a3\u30b3\u6a2a\u6d5c \u4f1a\u8b70\u30bb\u30f3\u30bf\u30fc.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2024\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Nakamura T, Xin He, Hattori N, Hida E, Hirata M. Dilemma in patients with amyotrophic lateral sclerosis and expectations from brain-machine interfaces. Annals of Medicine. Dec 2024. 56(1).<\/li>\n<li>Miwa K, Nakai M, Yoshimura S, Sasahara Y, Wada S, Koge J, Ishigami A, Yagita Y, Kamiyama K, Miyamoto Y, Kobayashi S, Minematsu K, Toyoda K, Koga Masatoshi. Clinical impact of body mass index on outcomes of ischemic and hemorrhagic strokes. International Journal of Stroke. Oct 2024. 19(8):907-915.<\/li>\n<li>Toyoda K, Yoshimura S, Nakai M, Wada S, Miwa K, Koge J, Yoshida T, Kamiyama K, Mizoue T, Hatano T, Yoshida Y, Sasahara Y, Ishigami A, Iwanaga Y, Miyamoto Y, Minematsu K, Kobayashi S, Koga M; Japan Stroke Data Bank Investigators. Severity, outcomes, and their secular changes in 33,870 ischemic stroke patients with atrial fibrillation in a hospital-based registry. Journal of Atherosclerosis and Thrombosis. Aug 2024.<\/li>\n<li>Akao M, Tomita H, Nakai M, Kodani E, Suzuki S, Hayashi K, Sawano M, Goya M, Yamashita T, Fukuda K, Tsuda T, Isobe M, Toyoda K, Miyamoto Y, Okamura T, Sasahara Y, Okumura K; J-RISK AF Research Group. A Novel Risk Score for Major Bleeding in Japanese Patients with Non-Valvular Atrial Fibrillation: The J-RISK AF Study. Journal of Atherosclerosis and Thrombosis. May 2024.<\/li>\n<li>Maeda M, Humber D, Hida E, Ohtani T, Wang G, Wu T, Takeda S, Situ J. N., Hayashi J, Nonen S, Takeda T, Okamoto H, Hori M, Sakata Y, Fujio Y, Tsunoda S. M. Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US patients: An international collaborative observational study. PLoS ONE. 2024; 19(3): e0299510.<\/li>\n<li>Nakamori M, Nakatani D, Sato T, Hasuike Y, Kon S, Saito T, Nakamura H, Takahashi M. P, Hida E, Komaki H, Matsumura T, Takada H, Mochizuki H. Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. eClinicalMedicine Part of THE LANCET Discovery Science. 2024;67: 102390.<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>\u5ca1\ufa11\u5468\u5e73, \u9ad8\u57a3\u5321\u5bff, \u6749\u672c\u8ce2\u4eba, \u6a29\u6cf0\u53f2, \u7b39\u539f\u7950\u4ecb, \u85e4\u5802\u8b19\u4e00, \u6a4b\u672c\u5f18\u884c, \u85e4\u672c\u5eb7\u502b, \u5742\u53e3\u5b66, \u98ef\u7530\u6df3\u4e00, \u5c71\u4e0a\u5b8f, \u85e4\u4e2d\u4fca\u4e4b, \u795e\u5409\u79c0\u660e, \u672c\u5c71\u9756, \u9ad9\u7530\u548c\u57ce, \u698a\u5b5d\u4e4b, \u9685\u5bff\u6075, \u85e4\u672c\u4eac\u5229, \u9ad8\u6a4b\u5927\u4ecb, \u5c71\u7530\u8207\u5fb3, \u6a2a\u6c5f\u52dd, \u897f\u5c3e\u96c5\u7f8e, \u5bfa\u5d0e\u6cf0\u548c, \u8c4a\u7530\u771f\u543e, \u5c71\u7530\u77e5\u7f8e, \u8cb4\u5cf6\u6674\u5f66, \u671b\u6708\u79c0\u6a39. \u8840\u6813\u56de\u53ce\u7642\u6cd5\u6642\u4ee3\u306e\u9662\u5185\u767a\u75c7\u8133\u6897\u585e\u306e\u7279\u5fb4OCR-STROKE\u30ec\u30b8\u30b9\u30c8\u30ea. STROKE2024. 2024\u5e743\u67087\u65e5-9\u65e5. \u30d1\u30b7\u30d5\u30a3\u30b3\u6a2a\u6d5c \u30ce\u30fc\u30b9.<\/li>\n<li>Okamura S, Hida E. Non-inferiority trials with evidence of assay sensitivity considering effect modification. ISCB 2024 Conference. 21-25 July 2024. Thessaloniki, Greece.<\/li>\n<li>Nishio K, Yamada T, Sakata Y, Hida E. Validation of EQ-5D-5L in patients with heart failure with preserved ejection fraction(HFpEF). ISCB 2024 Conference. 21-25 July 2024. Thessaloniki, Greece.<\/li>\n<li>\u5b89\u798f\u7950\u4e00, \u7c73\u7530\u5353\u53f8, \u7b39\u539f\u7950\u4ecb, \u4f50\u85e4\u502b\u6cbb, \u5c0f\u5c71\u9ad8\u53f2, \u60df\u9ad8\u88d5\u4e00, \u5c71\u53e3\u5b66, \u76f8\u7530\u822a, \u571f\u4e95\u5065\u592a\u90ce, \u5317\u897f\u7531\u6b66, \u98db\u7530\u82f1\u7950. COVID-19\u30d1\u30f3\u30c7\u30df\u30c3\u30af\u4e0b\u306b\u304a\u3051\u308b\u60a3\u8005\u306e\u53d7\u8a3a\u52d5\u5411\u8abf\u67fb: \u5927\u962a\u5927\u5b66\u533b\u5b66\u90e8\u9644\u5c5e\u75c5\u9662\u306eReal World Data\u3092\u7528\u3044\u305f\u6642\u7cfb\u5217\u5206\u6790\u306b\u3088\u308b\u7570\u5e38\u691c\u77e5\u306e\u8a66\u307f. \u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a\u7b2c15\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a. 2024\u5e743\u67087\u65e5-9\u65e5. \u30ca\u30ec\u30c3\u30b8\u30ad\u30e3\u30d4\u30bf\u30eb\u30b3\u30f3\u30b0\u30ec\u30b3\u30f3\u30d9\u30f3\u30b7\u30e7\u30f3\u30bb\u30f3\u30bf\u30fc<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2023\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Mensah GA, Fuster V, Murray CJL, Roth GA, on behalf of The Global Burden of Cardiovascular Diseases and Risks Collaborators (including Yasufuku Y). Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol. Dec 2023. 82(25): 2350-2473.<\/li>\n<li>Tateishi K*, Saito Y*, Yasufuku Y*, Nakagomi A* (*contributed equally), Kitahara H, Kobayashi Y, Tahara Y, Yonemoto N, Ikeda T, Sato N, Okura H. Prehospital predicting factors using a decision tree model for patients with witnessed out-of-hospital cardiac arrest and an initial shockable rhythm. Scientific Reports. Sep 2023. 13(1): 16180.<\/li>\n<li>Sato M, Akamatsu M, Shima T, Ikegami T, Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku, T, Okanoue T, Fujishiro M, Hida E, Koike K. Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial. The American Journal of Gastroenterology. August 2023. 118(8):1365-1372.<\/li>\n<li>Ishizuka T, Komaki H, Asahina Y, Nakamura H, Motohashi N, Takeshita E, Shimizu-Motohashi Y, Ishiyama A, Yonee C, Maruyama S, Hida E, Aoki Y. Systemic administration of the antisense oligonucleotide NS-089\/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I\/II clinical trial. Neuropsychopharmacology Reports. April 2023.<\/li>\n<li>Wataya T, Yanagawa M, Tsubamoto M, Sato T, Nishigaki D, Kita K, Yamagata K, Suzuki Y, Hata A, Kido S, Tomiyama N for the Osaka University Reading Team. Radiologists with and without deep learning\u2013based computer-aided diagnosis: comparison of performance and interobserver agreement for characterizing and diagnosing pulmonary nodules\/masses. European Radiology. January 2023. 33(1):348-359.<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>\u5b89\u798f\u7950\u4e00, \u897f\u5ca1\u7950\u4e00, \u5c71\u53e3\u4f73\u5c0f\u91cc, \u8d64\u7fbd\u5b66, \u4eca\u6751\u77e5\u660e. NDB\u30aa\u30fc\u30d7\u30f3\u30c7\u30fc\u30bf\u7b49\u3092\u5229\u7528\u3057\u305f\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u9700\u8981\u306e\u5c06\u6765\u63a8\u8a08. \u7b2c82\u56de\u65e5\u672c\u516c\u8846\u885b\u751f\u5b66\u4f1a\u7dcf\u4f1a. 2023\u5e7410\u670831\u65e5-11\u67082\u65e5. \u3064\u304f\u3070\u56fd\u969b\u4f1a\u8b70\u5834.<\/li>\n<li>Okamura S, Hida E. Non-inferiority trials with evidence of assay sensitivity using population adjustment method. ISCB 2023 Conference. 27-31 August 2023. Milan, Italy.<\/li>\n<li>Sato T, Hida E. Clinical trial design and estimation methods that can yield additional information than single-arm trials. ISCB 2023 Conference. 27-31 August 2023. Milan, Italy.<\/li>\n<li>\u5b89\u798f\u7950\u4e00(\u62db\u8058\u8b1b\u6f14). RADISH\u30ef\u30fc\u30ad\u30f3\u30b0\u30b0\u30eb\u30fc\u30d7\u4f01\u753b Year in review \u300c\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u9818\u57df\u306b\u304a\u3051\u308bD&amp;I\u7814\u7a76\u300d. \u666e\u53ca\u3068\u5b9f\u88c5(RADISH)\u79d1\u5b66\u7814\u7a76\u4f1a \u7b2c9\u56de\u5b66\u8853\u96c6\u4f1a. 2023\u5e747\u67081\u65e5. \u30a6\u30a4\u30f3\u30af\u3042\u3044\u3061.<\/li>\n<li>\u98db\u7530\u82f1\u7950(\u30aa\u30fc\u30ac\u30ca\u30a4\u30b6). \u4f01\u753b\u30bb\u30c3\u30b7\u30e7\u30f3\u300c\u30aa\u30fc\u30d7\u30f3\u30b5\u30a4\u30a8\u30f3\u30b9\u63a8\u9032\u306b\u5411\u3051\u305f\u7523\u5b66\u306b\u304a\u3051\u308b\u30c7\u30fc\u30bf\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3068\u5229\u6d3b\u7528\u306e\u53d6\u7d44\u3068\u5c55\u671b\u300d. \u7b2c37\u56de\u4eba\u5de5\u77e5\u80fd\u5b66\u4f1a\u5168\u56fd\u5927\u4f1a. 2023\u5e746\u67086\u65e5-9\u65e5. \u718a\u672c\u57ce\u30db\u30fc\u30eb.<\/li>\n<li>\u7b39\u539f\u7950\u4ecb. Association of Residence-Hospital Distance and Discharge Outcomes in Cardiovascular Disease Patients.\u7b2c87\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a(JCS2023). 2023\u5e743\u670810\u65e5-12\u65e5. \u798f\u5ca1\u30b5\u30f3\u30d1\u30ec\u30b9.<\/li>\n<li>\u4f50\u85e4\u502b\u6cbb, \u9ad8\u6a4b\u7950\u7b56, \u60df\u9ad8\u88d5\u4e00, \u7c73\u7530\u5353\u53f8, \u5c0f\u5c71\u9ad8\u53f2, \u5317\u897f\u7531\u6b66, \u98db\u7530\u82f1\u7950. \u533b\u7642\u60c5\u5831\u30c7\u30fc\u30bf\u304b\u3089\u898b\u308bCOVID-19\u306e\u5f71\u97ff\u8abf\u67fb. \u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a\u7b2c14\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a. 2023\u5e742\u67089\u65e5-10\u65e5. \u77f3\u5ddd\u770c\u7acb\u97f3\u697d\u5802.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2022\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li><\/li>\n<li>Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer. December 2022. 22(1):1292.<\/li>\n<li>Egashira R, Sato T, Miyake A, Takeuchi M, Nakano M, Saito H, Moriguchi M, Tonari S, Hagihara K. The Japan Frailty Scale is a promising screening test for frailty and pre-frailty in Japanese elderly people. Gene. November 2022. 844.\u00a0<\/li>\n<li>\u8352\u6728\u6d69\u4e4b, \u60df\u9ad8\u88d5\u4e00, \u4f50\u85e4\u502b\u6cbb, \u9577\u8c37\u5ddd\u8cb4\u5927, \u5c0f\u6797\u5178\u5f18, \u5c71\u7530\u77e5\u7f8e, \u98db\u7530\u82f1\u7950. \u533b\u5b66\u7814\u7a76\u306b\u4e8c\u6b21\u5229\u7528\u3059\u308b\u305f\u3081\u306e\u533b\u7642\u60c5\u5831\u30c7\u30fc\u30bf\u306e\u7279\u5fb4\u30fb\u6027\u8cea\u8abf\u67fb \u2014\u5927\u962a\u5927\u5b66\u533b\u5b66\u90e8\u9644\u5c5e\u75c5\u9662 \u5358\u65bd\u8a2d\u306e\u72b6\u6cc1\u2014. \u85ac\u7406\u3068\u6cbb\u7642\uff08JPT\uff09\u5897\u520a\u53f7\uff08\u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a\u96d1\u8a8c 23\uff09, 2022\u5e748\u6708. \u7b2c50\u5dfb \u5897\u520a1\u53f7: 37-50.<\/li>\n<li>Takedachi M, Shimabukuro Y, Sawada K, Koshimizu M, Shinada K, Asai H, Mizoguchi A, Hayashi Y, Tsukamoto A, Miyago M, Nishihara F, Nishihata T, Shimabukuro M, Kurakami H, Sato T, Hamazaki Y, Iwayama T, Fujihara C, Murakami S. Evaluation of periodontitis-related tooth loss according to the new 2018 classification of periodontitis. Scientific Reports. July 2022. 12(1).<\/li>\n<li>Hayama M, Maeda Y, Shikina T, Tatehara S, Inokuchi G, Jeffrey B Hoag, Sato T, Obata S, Nakatani A, Amano Y, Hida E, Nibu K, Inohara H. Validation of epistaxis severity score for hereditary hemorrhagic telangiectasia in Japan. Auris Nasus Larynx. June 2022. 49(3):415-420.<\/li>\n<li>Arase N, Tsuji H, Takamatsu H, Jin H, Konaka H, Hamaguchi Y, Tonomura K, Kotobuki Y, Ueda-Hayakawa I, Matsuoka S, Hirano T, Yorifuji H, Murota H, Ohmura K, Nakashima R, Sato T, Kumanogoh A, Katayama I, Arase H, Fujimoto M. Cell surface-expressed Ro52\/IgG\/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies. Journal of Autoimmunity. January 2022. 126(9).<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>Tabayashi M ,Sato T, Kikuchi R, Kawahara T, Yamazaki A. Development and validation of the Japanese version of the Paternal Antenatal Attachment Scale. 25th East Asian Forum of Nursing Scholars Conference. 21-22 April 2022. Web\u958b\u50ac.<\/li>\n<li>\u8352\u6728\u6d69\u4e4b, \u60df\u9ad8\u88d5\u4e00, \u4f50\u85e4\u502b\u6cbb, \u5c71\u7530\u77e5\u7f8e, \u98db\u7530\u82f1\u7950. \u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30c7\u30fc\u30bf\u3092\u69cb\u6210\u3059\u308b\u533b\u7642\u60c5\u5831\u30c7\u30fc\u30bf\u306e\u7279\u5fb4\u3068\u6027\u8cea\u306b\u3064\u3044\u3066. \u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a \u7b2c13\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a. 2022\u5e742\u67084\u65e5-5\u65e5. Web\u958b\u50ac.<\/li>\n<li>\u7247\u5ca1\u8475, \u798f\u4e95\u656c\u7950, \u4f50\u85e4\u502b\u6cbb, \u897f\u5ca1\u5927\u8f14, \u83ca\u6c60\u5b8f\u5e78, \u4e95\u4e0a\u8302, \u8fd1\u85e4\u5c1a\u5df1, \u4e2d\u8c37\u53cb\u6a39, \u4f0a\u85e4\u3086\u308a. \u4eba\u53e3\u898f\u6a21\u30fb\u793e\u4f1a\u7d4c\u6e08\u72b6\u6cc1\u3092\u8003\u616e\u3057\u305f\u5065\u5eb7\u5bff\u547d\u306e\u90fd\u9053\u5e9c\u770c\u5185\u683c\u5dee\u306e\u8a08\u6e2c. \u7b2c32\u56de\u65e5\u672c\u75ab\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a. 2022\u5e741\u670827\u65e5, Web\u958b\u50ac.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2021\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>\u5927\u8c37\u76f4\u7531, \u5869\u5d0e\u6b63\u5e78, \u4e45\u672c\u4f73\u5948, \u6c34\u57ce\u53f2\u8cb4, \u8352\u6728\u6d69\u4e4b, \u7530\u5c3b\u6dbc, \u7a32\u7530\u5b9f\u679d\u5b50, \u80a5\u7530\u5178\u5b50, \u6709\u7530\u60a6\u5b50, \u677e\u91ce\u5eb7\u5b50, \u771f\u7530\u660c\u723e. \u591a\u8077\u7a2e\u5354\u8abf\u578b\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u306e\u6210\u679c\u7269\u3068\u3057\u3066\u306e\u30d7\u30ed\u30c8\u30b3\u30eb\u7d20\u6848\u4f5c\u6210\u306b\u95a2\u3059\u308b\u8003\u5bdf. \u81e8\u5e8a\u85ac\u7406. November 2021. 52(6): 165-173.<\/li>\n<li>Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, Hida E. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial. European Heart Journal. October 2021. 42(40): 4111-4122.<\/li>\n<li>Kataoka A, Fukui K, Sato T, Kikuchi H, Inoue S, Kondo N, Nakaya T, Ito Y. Geographical socioeconomic inequalities in healthy life expectancy in Japan, 2010-2014: An ecological study. The Lancet Regional Health &#8211; Western Pacific. 1 September 2021. 14.\u00a0<\/li>\n<li>Yamashita K, Miyazaki Y, Nakatani D, Masuike Y, Tanaka K, Sugimura K, Makino T, Shiraishi O, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Kimura Y, Araki H, Yamada T, Yasuda T, Yano M, Eguchi H, Doki Y. OSK-0028 in Patients With Esophageal Cancer Undergoing Esophagectomy: A Double-blind, Randomised Controlled Trial. Anticancer Research. August 2021. 41(8): 3875-3884.<\/li>\n<li>Sato S, Ukimoto S, Kanamoto T, Sasaki N, Hashimoto T, Saito H, Hida E, Sato T, Mae T, Nakata K. Chronic musculoskeletal pain, catastrophizing, and physical function in adult women were improved after 3-month aerobic-resistance circuit training. Scientific Reports. 22 July 2021. 11.<\/li>\n<li>Yamaji T, Harada T, Hashimoto Y, Takaeko Y, Kajikawa M, Han Y, Maruhashi T, Kishimoto S, Hashimoto H, Kihara Y, Hida E, Chayama K, Goto C, FM Yusoff, Nakashima A, Higashi Y. Inconvenient relationship of haemoglobin A1c level with endothelial function in type 2 diabetes in a cross-sectional study. BMJ open. 9 June 2021. 11(6).<\/li>\n<li>Kawahara T, Sugita Y, Momose H, K. M. Szymanski, Hida E, Yamazaki A. Development and Validation of the Japanese Version of Quality of Life Assessment of Spina Bifida in Children (QUALAS-C-J).\u00a0 Pediatrics International. April 2021. 63(4): 423-429.<\/li>\n<li>Kajikawa M, Maruhashi T, Kishimoto S, Hashimoto H, Takaeko Y, Yamaji T,\u00a0Harada T, Hashimoto Y, Han Y, Kihara Y, Hida E, Chayama K, Goto C, Yusoff FM,\u00a0 Nakashima A, Higashi Y. Association of Body Mass Index with Endothelial Function in Asian Men. International Journal of Cardiology. 1 February 2021. 324: 186-192.<\/li>\n<li>Kario K, Nomura A, Kato A, Harada N, Tanigawa T, So R, Suzuki S, Hida E, Satake K. Digital therapeutics for essential hypertension using a smartphone application: A randomized, open-label, multicenter pilot study. The Journal of Clinical Hypertension. 23 January 2021.<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>Hida E, Tango T. Non-inferiority trials with indirect evidence of assay sensitivity using network meta-analysis. ISCB 2021 Conference. 18-22 July 2021. Lyon, France.<\/li>\n<li>Miyake A, Sato T, Yamada T, Hida E. One small clinical trial design to provide additional evidence of treatment effects than single-arm trials. ISCB 2021 Conference. 18-22 July 2021. Lyon, France.<\/li>\n<li>\u4f50\u85e4\u502b\u6cbb, \u4e09\u5b85\u9855\u5149, \u5c71\u7530\u77e5\u7f8e, \u98db\u7530\u82f1\u7950. \u5358\u7fa4\u8a66\u9a13\u306b\u304a\u3051\u308b\u6cbb\u7642\u52b9\u679c\u306b\u4e0e\u3048\u308b\u30d0\u30a4\u30a2\u30b9\u306e\u5f71\u97ff\u3092\u8efd\u6e1b\u3059\u308b\u8a66\u9a13\u30c7\u30b6\u30a4\u30f3\u306e\u63d0\u6848. 2021\u5e74\u5ea6\u65e5\u672c\u8a08\u91cf\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a. 2021\u5e745\u670813\u65e5-14\u65e5. Web\u958b\u50ac.<\/li>\n<li>\u8352\u6728\u6d69\u4e4b, \u60df\u9ad8\u88d5\u4e00, \u4f50\u85e4\u502b\u6cbb, \u5c71\u7530\u77e5\u7f8e, \u98db\u7530\u82f1\u7950. RWD\u306e\u9069\u5207\u306a\u5229\u6d3b\u7528\u65b9\u6cd5\u306e\u691c\u8a0e \uff0d\u533b\u7642\u60c5\u5831\u30c7\u30fc\u30bf\u306e\u7279\u5fb4\u3068\u50be\u5411\u306e\u628a\u63e1\uff0d. \u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a \u7b2c12\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a. 2021\u5e742\u670812\u65e5-13\u65e5. Web\u958b\u50ac.<\/li>\n<li>\u7247\u5ca1\u8475, \u798f\u4e95\u656c\u7950, \u4f50\u85e4\u502b\u6cbb, \u83ca\u6c60\u5b8f\u5e78, \u4e95\u4e0a\u8302, \u8fd1\u85e4\u5c1a\u5df1, \u4e2d\u8c37\u53cb\u6a39, \u4f0a\u85e4\u3086\u308a.\u00a0\u90fd\u9053\u5e9c\u770c\u5185\u306e\u5065\u5eb7\u5bff\u547d\u30fb\u5e73\u5747\u5bff\u547d\u306e\u793e\u4f1a\u7d4c\u6e08\u683c\u5dee\u3068\u90fd\u9053\u5e9c\u770c\u5168\u4f53\u306e\u5065\u5eb7\u6307\u6a19\u306b\u304a\u3051\u308b\u95a2\u9023\u6027\u306e\u691c\u8a0e.\u00a0\u7b2c31\u56de\u65e5\u672c\u75ab\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a.\u00a02021\u5e741\u670827\u65e5-29\u65e5. Web\u958b\u50ac.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2020\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Kato M, Hayashi Y, Uema R, Saiki H, Kimura K, Inoue T, Sakatani A, Yoshii S, Tsujii Y, Shinzaki S, Hida E, Iijima H, Takehara T. Usefulness of a dedicated mouthpiece for the Valsalva maneuver to visualize the hypopharynx during transoral endoscopy. Endoscopy International Open. 2020. 8: E536-E543.<\/li>\n<li>Masaki K, Tateno H, Nomura A, Muto T, Suzuki S, Satake K, Hida E, Fukunaga K. A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker. NPJ Digital Medicine. 2020. 3: 35.<\/li>\n<li>Sato T, Inatsu Y. A\u00a0<i>Cp<\/i>\u00a0type criterion for model selection in the GEE method when both scale and correlation parameters are unknown. Hiroshima Mathematical Journal. 2020. 50(1): 85-115.<\/li>\n<li>Sato T. Asymptotic bias of <i>Cp\u00a0<\/i>type criterion for model selection in the GEE when the sample size and the cluster sizes are large. Hiroshima Mathematical Journal. 2020. 50(2): 223-251.<\/li>\n<li>Takaeko Y, Matsui S, Kajikawa M, Maruhashi T, Yamaji T, Harada T, Han Y, Hashimoto H, Kihara Y, Hida E, Chayama K, Goto C, Aibara Y, Yusoff FM, Kishimoto S, Nakashima A, Higashi Y. Relationship between high-density lipoprotein cholesterol levels and endothelial function in women: a cross-sectional study. BMJ Open. 2020. 10(7).<\/li>\n<li>Watadani Y, Ohge H, Hashimoto Y, Kondo N, Sakashita Y, Uemura K, \u00a0Miyamoto K, Murakami Y, Hida E, Sueda T. Validating the Japanese version of the Gastrointestinal Quality of Life Index (GIQLI) questionnaire. Annals of Gastroenterological Surgery. 2020. 00:1-5<\/li>\n<li>Kawahara T, Sugita Y, Momose\u00a0H, Szymanski KM, Hida E, Yamazaki\u00a0A.\u00a0Development and Validation of the Japanese Version of Quality of Life Assessment of Spina Bifida in Children (QUALAS-C-J). Pediatrics International. 03 August 2020.<\/li>\n<li>Kario\u00a0K, Nomura\u00a0A, Harada\u00a0N, Tanigawa\u00a0T, So\u00a0R, Nakagawa\u00a0K, Suzuki\u00a0S, Okura\u00a0A, Hida\u00a0E, Satake\u00a0K. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB\u2010DH1 trial.\u00a0The Journal of Clinical Hypertension. 20 August 2020.<\/li>\n<li>Kajikawa M, Maruhashi T, Kishimoto S, Hashimoto H, Takaeko Y, Yamaji T, Harada T, Hashimoto Y, Han Y, Kihara Y, Hida E, Chayama K, Goto C, Yusoff FM, Nakashima A, Higashi Y.\u00a0Association of Body Mass Index with Endothelial Function in Asian Men.\u00a0Int J Cardiol. 12 September 2020.<\/li>\n<li>Yamaji T, Harada T, Hashimoto Y, Takaeko Y, Kajikawa M, Kihara Y, Hida E, Chayama K, Goto C, Han Y, Yusoff FM, Kishimoto S, Maruhashi T, Nakashima A, Higashi Y.\u00a0Pre-impaired fasting glucose state is a risk factor for endothelial dysfunction: Flow-mediated Dilation Japan (FMD-J) study.\u00a0BMJ Open Diabetes Res Care. October 2020. 8(1).<\/li>\n<li>Takaeko Y, Kajikawa M, Kishimoto S, Yamaji T, Harada T, Han Y, Kihara Y, Hida E, Chayama K, Goto C, Aibara Y,\u00a0Yusoff FM,\u00a0Maruhashi T, Nakashima A, Higashi Y. Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy.\u00a0Journal of Clinical Medicine. November 2020. 9(12).<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>Hida E, Tango\u00a0T.\u00a0Can we evaluate assay sensitivity in a non-inferiority trial ?.\u00a0ISCB Conference 2020. Aug 23-27. Krak\u00f3w, Poland.<\/li>\n<li>Miyake A, Sato T, Yamada T, Hida\u00a0E.\u00a0One small clinical trial design to provide additional information than single arm trials.\u00a0ISCB Conference 2020. Aug 23-27. Krak\u00f3w, Poland.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2019\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Kawahara T, Sugita Y, Momose H, Szymanski KM, Hida E, Yamazaki A. Development and Validation of the Japanese Version of Quality of Life Assessment of Spina Bifida in Teenagers (QUALAS-T-J). Pediatrics International. 2019.<\/li>\n<li>Takaeko Y, Matsui S, Kajikawa M, Maruhashi T, Kishimoto S, Hashimoto H, Kihara Y, Hida E, Chayama K, Goto C, Aibara Y, Yusoff FM, Noma K, Nakashima A, Higashi Y. Association of extremely high levels of high-density lipoprotein cholesterol with endothelial dysfunction in men. Journal of Clinical Lipidology. 2019. 13(4).<\/li>\n<li>Tanigawa T, Nomura A, Kuroda M, Muto T, Hida E, Satake K. Comparing Telemedicine and Face-to-Face Consultation Based on the Standard Smoking Cessation Program for Nicotine Dependence: Protocol for a Randomized Controlled Trial. Journal of medical internet research, research protocols. 2019. 8(7).<\/li>\n<li>Nomura A, Tanigawa T, Muto T, Oga T, Fukushima Y, Kiyosue A, Miyazaki M, Hida E, Satake K. Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial. Journal of Medical Internet Research. 2019. 21(4).<\/li>\n<li>Nomura A, Tateno H, Masaki K, Muto T, Suzuki S, Satake K, Hida E, Fukunaga K. A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2019. 8(2).<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>\u8352\u6728 \u6d69\u4e4b. \u81e8\u5e8a\u7814\u7a76\u30c7\u30fc\u30bf\u306e\u54c1\u8cea\u7ba1\u7406\u306e\u305f\u3081\u306e\u64cd\u4f5c\u6027\u3068\u6c4e\u7528\u6027\u306e\u9ad8\u3044\u30d7\u30ed\u30b0\u30e9\u30e0\u958b\u767a. ARO\u5354\u8b70\u4f1a\u7b2c7\u56de\u5b66\u8853\u96c6\u4f1a. 2019\u5e749\u670826\u65e5-28\u65e5. \u6771\u5317\u5927\u5b66.<\/li>\n<li>Hida E, Yamaoka K, Tango T. Consideration of the assay sensitivity for non-inferiority trials using network meta-analysis.\u00a0ISCB Conference 2019. Jul 14-18. Leuven, Bergium.<\/li>\n<li>Miyake A, Yamada T,\u00a0 Hida E. One small clinical trial design to improve single arm trials in rare diseases.\u00a0ISCB Conference 2019. Jul 14-18. Leuven, Bergium.<\/li>\n<li>\u98db\u7530 \u82f1\u7950.\u00a0\u00a0\u7d71\u8a08\u3092\u5c02\u9580\u3068\u3057\u306a\u3044\u62c5\u5f53\u8005\u306b\u77e5\u3063\u3066\u304a\u3044\u3066\u307b\u3057\u3044\u7d71\u8a08\u5b66\u7684\u306a\u8996\u70b9 \u2212\u81e8\u5e8a\u7814\u7a76\u306b\u5fc5\u8981\u3068\u306a\u308b5 \u3064\u306e\u30dd\u30a4\u30f3\u30c8\u2212.\u00a0\u65e5\u672c\u81e8\u5e8a\u8a66\u9a13\u5b66\u4f1a\u7b2c10\u56de\u5b66\u8853\u96c6\u4f1a\u7dcf\u4f1a.\u00a02019\u5e741\u670825\u65e5-26\u65e5.\u00a0TFT\u30db\u30fc\u30eb\uff08\u6771\u4eac\uff09.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2018\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Hida E, Tango T. Design and analysis of a three-arm non-inferiority trial with a prespecified margin for the hazard ratio. Pharmaceutical Statistics.\u00a0 2018. 17(5): 489-503.<\/li>\n<li>Ikeda Y, Ishii S, Yazaki M, Fujita T, Iida Y, Kaida T, Nabeta T, Nakatani E, Maekawa E, Yanagisawa T, Koitabashi T, Inomata T, Ako J. Portal congestion and intestinal edema in hospitalized patients with heart failure. Heart and vessels. 2018. 33(7): 740-751.<\/li>\n<li>Matsui S, Kajikawa M, Maruhashi T, Iwamoto Y, Oda N, Kishimoto S, Hashimoto H, Hidaka T, Kihara Y, Chayama K, Hida E, Goto C, Aibara Y, Nakashima A, Yusoff FM, Noma K, Kuwahara Y, Matsubara A, Higashi Y. Endothelial dysfunction, abnormal vascular structure and lower urinary tract symptoms in men and women. International Journal of Cardiology. 2018. 261: 196-203.<\/li>\n<li>Ikawa F, Abiko M, Ishii D, Ohshita J, Matsushige T, Okazaki T, Sakamoto S, Hida E, Kobayashi S, Kurisu K. Analysis of outcome at discharge after aneurysmal subarachnoid hemorrhage in Japan according to the Japanese stroke databank. Neurosurgical Review. 2018. 41(2): 567-574.<\/li>\n<li>Akagi-Kurashige Y, Tsujikawa A, Yuzawa M, Ishibashi T, Nakanishi H, Nakatani E, Teramukai S, Fukushima M, Yoshimura N, AMD2000 study group. A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study. Japanese journal of ophthalmology. 2018. 62(2): 137-143.<\/li>\n<li>Tsujikawa A, Akagi-Kurashige Y, Yuzawa M, Ishibashi T, Nakanishi H, Nakatani E, Teramukai S, Fukushima M, Yoshimura N, AMD2000 Study Group. Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report. Japanese journal of ophthalmology. 2018. 62(2): 127-136.<\/li>\n<li>Tanaka H, Nakatani E, Fukutomi Y, Sekiya K, Kaneda H, Iikura M, Yoshida M, Takahashi K, Tomii K, Nishikawa M, Kaneko N, Sugino Y, Shinkai M, Ueda T, Tanikawa Y, Shirai T, Hirabayashi M, Aoki T, Kato T, Iizuka K, Fujii M, Taniguchi M. Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study. Allergy. 2018. 73(5): 1110-1118.<\/li>\n<li>Morimoto C, Hida E, Shima K, Okamura H.Temporal Processing Instability with Millisecond Accuracy is a Cardinal Feature of Sensorimotor Impairments in Autism\u00a0 Spectrum Disorder: Analysis Using the Synchronized Finger-Tapping Task. Journal of\u00a0 Autism and Development Disorders. 2018. 48(2): 351-360.<\/li>\n<li>Tsubokawa N, Tsutani Y, Miyata Y, Handa Y, Misumi K, Hanaki H, Hida E, Okada M. Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World Journal of Surgery. 2018. 42(8): 2493-2501.<\/li>\n<li>Hayashi H, Fukutomi Y, Mitsui C, Nakatani E, Watai K, Kamide Y, Sekiya K, Tsuburai T, Ito S, Hasegawa Y, Taniguchi M. Smoking Cessation as a Possible Risk Factor for the Development of Aspirin-Exacerbated Respiratory Disease in Smokers. J Allergy Clin Immunol Pract. 2018. 6(1): 116-125. e3.<\/li>\n<li>Toda M, Nakatani E, Omae K, Fukushima M, Chin T. Age-specific characterization of spinal cord injuries over a 19-year period at a Japanese rehabilitation center. PloS one. 2018. 13(3): e0195120.<\/li>\n<li>Yokoi A, Hasegawa T, Oshima Y, Higashide S, Nakatani E, Kaneda H, Kawamoto A, Nishijima E. Clinical outcomes after tracheoplasty in patients with congenital tracheal stenosis in 1997-2014. Journal of pediatric surgery. 2018. 53(11): 2140-2144.<\/li>\n<li>Nishio H, Iwata T, Nomura H, Morisada T, Takeshima N, Takano H, Sasaki H, Nakatani E, Teramukai S, Aoki D. Liquid-based cytology versus conventional cytology for detection of uterine cervical lesions: a prospective observational study. Japanese Journal of Clinical Oncology. 2018. 48(6): 522-528.<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>\u8352\u6728 \u6d69\u4e4b. \u30a2\u30ab\u30c7\u30df\u30a2\u5411\u3051\u306e\u4e2d\u592e\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u624b\u6cd5\u306e\u958b\u767a\u3068\u5b9f\u88c5.\u00a0ARO\u5354\u8b70\u4f1a\u7b2c6\u56de\u5b66\u8853\u96c6\u4f1a. 2018\u5e748\u670830\u65e5-9\u67081\u65e5. \u4e5d\u5dde\u5927\u5b66.<\/li>\n<li>\u6728\u6751 \u6075\u5b50, \u8352\u6728 \u6d69\u4e4b. \u5927\u962a\u5927\u5b66\u533b\u5b66\u90e8\u9644\u5c5e\u75c5\u9662\u672a\u6765\u533b\u7642\u958b\u767a\u90e8\u30c7\u30fc\u30bf\u30bb\u30f3\u30bf\u30fc\u3067\u306eQMS\u6d3b\u52d5\u306b\u95a2\u3059\u308b\u53d6\u308a\u7d44\u307f.\u00a0ARO\u5354\u8b70\u4f1a\u7b2c6\u56de\u5b66\u8853\u96c6\u4f1a. 2018\u5e748\u670830\u65e5-9\u67081\u65e5. \u4e5d\u5dde\u5927\u5b66.<\/li>\n<li>Hida E, Tango T. One approach to the assurance of assay sensitivity in non-inferiority trials with network meta-analysis. ISCB Conference 2018. Aug 26-30. Melbourne, Australia.<\/li>\n<li>Hida E, Tango T. Consideration of three-arm non-inferiority trial design and analysis with a prespecified margin for a survival endpoint. XXIXth International Biometric Conference. 2018 Jul 8-13. Barcelona, Spain.<\/li>\n<\/ul>\n<\/div>\n<div class=\"content\">\n<h3 class=\"m_o0\">2017\u5e74<\/h3>\n<h4>\u539f\u8457<\/h4>\n<ul>\n<li>Maruhashi T, Iwamoto Y, Kajikawa M, Oda N, Kishimoto S, Matsui S, Hashimoto H, Aibara Y, Yusoff FM, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Hida E, Higashi Y. Interrelationships Among Flow-Mediated Vasodilation, Nitroglycerine-Induced Vasodilation, Baseline Brachial Artery Diameter, Hyperemic Shear Stress, and Cardiovascular Risk Factors. Journal of the\u00a0 American Heart Association. 2017. 7(1) .<\/li>\n<li>Omae K, Kanemaru SI, Nakatani E, Kaneda H, Nishimura T, Tona R, Naito Y, Kawamoto A, Fukushima M. Regenerative treatment for tympanic membrane perforation using gelatin sponge with basic fibroblast growth factor. Auris Nasus Larynx. 2017. 44(6): 664-671.<\/li>\n<li>Makino Y, Yokota H, Nakatani E, Yajima D, Inokuchi G, Motomura A, Chiba F, Torimitsu S, Uno T, Iwase H. Differences between postmortem CT and autopsy in death investigation of cervical spine injuries. Forensic science international. 2017. 281: 44-51.<\/li>\n<li>Morisada T, Teramoto K, Takano H, Sakamoto I, Nishio H, Iwata T, Hashi A, Katoh R, Okamoto A, Sasaki H, Nakatani E, Teramukai S, Aoki D. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women. Cancer epidemiology. 2017. 50(Pt A): 60-67.<\/li>\n<li>Matsui S, Kajikawa M, Hida E, Maruhashi T, Iwamoto Y, Iwamoto A, Oda N, Kishimoto S, Hidaka T, Kihara Y, Chayama K, Goto C, Aibara Y, Nakashima A, Yusoff FBM, Noma K, Higashi Y. Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Na\u00efve Individuals. Scientific Reports. 2017. 7: 1-10.<\/li>\n<li>Watanabe M, Nakatani E, Yoshikawa H, Kanno T, Nariai Y, Yoshino A, Vieth M, Kinoshita Y, Sekine J. Oral soft tissue disorders are associated with gastroesophageal reflux disease: retrospective study. BMC gastroenterology. 2017. 17(1): 92.<\/li>\n<li>Sekine J, Nakatani E, Hideshima K, Iwahashi T, Sasaki H. Diagnostic accuracy of oral cancer cytology in a pilot study. Diagnostic pathology. 2017. 12(1): 27.<\/li>\n<li>Hanaoka M, Yasuno M, Ishiguro M, Yamauchi S, Kikuchi A, Tokura M, Ishikawa T, Nakatani E, Uetake H. Morphologic change of the psoas muscle as a surrogate marker of sarcopenia and predictor of complications after colorectal cancer surgery. International journal of colorectal disease. 2017. 32(6): 847-856.<\/li>\n<li>Kajikawa M, Hida E, Kihara Y, Yamagishi SI, Higashi Y. Response to &#8220;circulating level of pigment epithelium-derived factor is associated with vascular function and structure: Methodological issues&#8221;. International Journal of Cardiology. 2017. 229: 121.<\/li>\n<li>\u4e2d\u8c37 \u82f1\u4ec1. \u9769\u65b0\u7684\u533b\u7642\u7814\u7a76\u958b\u767a\u3067\u6311\u3080\u795e\u7d4c\u5909\u6027\u75be\u60a3 \u30d7\u30ea\u30aa\u30f3\u75c5\u6cbb\u9a13\u4f53\u5236\u306e\u78ba\u7acb\u306b\u5411\u3051\u3066 \u30d7\u30ea\u30aa\u30f3\u75c5\u5236\u5727\u6226\u7565 \u672c\u90a6\u306b\u304a\u3051\u308b\u5b64\u767a\u6027CJD\u306e\u5730\u57df\u96c6\u7a4d\u6027\u3068\u81e8\u5e8a\u75c7\u72b6\u306b\u3088\u308b\u4e88\u5f8c\u5206\u985e \u96e3\u6cbb\u6027\u75be\u60a3\u514b\u670d\u7814\u7a76\u4e8b\u696d\u30c7\u30fc\u30bf\u306e\u89e3\u6790. \u81e8\u5e8a\u8a55\u4fa1. 2017. 44(4): 673-679.<\/li>\n<\/ul>\n<h4>\u5b66\u4f1a\u7b49\u767a\u8868<\/h4>\n<ul>\n<li>\u98db\u7530 \u82f1\u7950. \u81e8\u5e8a\u7814\u7a76\u30fb\u6cbb\u9a13\u306e\u7d71\u8a08\u89e3\u6790-\u81e8\u5e8a\u7814\u7a76\u30fb\u6cbb\u9a13\u5f93\u4e8b\u8005\u304c\u5099\u3048\u308b\u3079\u304d\u751f\u7269\u7d71\u8a08\u306e\u57fa\u790e-. \u5e73\u621029\u5e74\u5ea6\u81e8\u5e8a\u7814\u7a76\u30fb\u6cbb\u9a13\u5f93\u4e8b\u8005\u7814\u4fee. 2017\u5e7412\u670816\u65e5. \u5ca1\u5c71\u5927\u5b66.<\/li>\n<li>Hida E, Yamaoka K, Tango T. Consideration of hybrid non-inferiority trials design using network-meta-analysis. 38th Annual Conference of the International Society for Clinical Biostatistics. 2017 July 9-13. Vigo, Spain.<\/li>\n<li>Hida E, Tango T. The design of non-inferiority trial using Network Meta-Analysis to assess the assay sensitivity. Joint Conference on Biometrics &amp; Biopharmaceutical Statistics. 2017 Aug 28- Sep 1. Vienna, Austria.<\/li>\n<li>\u8352\u6728 \u6d69\u4e4b. \u53ef\u8996\u5316\u30bd\u30d5\u30c8\u3092\u5229\u7528\u3057\u305f\u30c7\u30fc\u30bf\u30ec\u30d3\u30e5\u30fc. \u5e73\u621029\u5e74\u5ea6\u30c7\u30fc\u30bf\u30de\u30cd\u30fc\u30b8\u30e3\u30fc\u990a\u6210\u7814\u4fee. 2017\u5e7412\u670817\u65e5. \u5927\u962a\u5927\u5b66\uff0e<\/li>\n<li>\u8352\u6728 \u6d69\u4e4b, \u4e45\u4fdd \u5fe0\u53f8, \u6728\u6751 \u6075\u5b50, \u5009\u4e0a \u5f18\u5e78, \u4e09\u5b85 \u9855\u5149, \u5c71\u672c \u5c1a\u5b50, \u5c71\u7530 \u77e5\u7f8e, \u897f\u7530 \u5e78\u4e8c. \u30c7\u30fc\u30bf\u30de\u30cd\u30fc\u30b8\u30e3\u30fc\u3068\u7d71\u8a08\u5bb6\u306e\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u30bb\u30df\u30ca\u30fc . ARO\u5354\u8b70\u4f1a\u7b2c5\u56de\u5b66\u8853\u96c6\u4f1a. 2017\u5e749\u670825\u65e5-27\u65e5. \u30a6\u30a4\u30f3\u30af\u3042\u3044\u3061\uff08\u611b\u77e5\uff09.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"\u672c\u8b1b\u5ea7\u306e\u8ad6\u6587\u3001\u53e3\u982d\u767a\u8868\u7b49\u3001\u7814\u7a76\u6210\u679c\u3092\u63b2\u8f09\u3057\u3066\u3044\u307e\u3059\u3002","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/pages\/8"}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/comments?post=8"}],"version-history":[{"count":129,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/pages\/8\/revisions"}],"predecessor-version":[{"id":749,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/pages\/8\/revisions\/749"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/bsds\/wp-json\/wp\/v2\/media?parent=8"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}